Cellectis S.A.
$3.30▲ 12.44%(+$0.36)
TickerSpark Score
51/100
▌ Mixed
65
Valuation
40
Profitability
55
Growth
64
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLLS research report →
52-Week Range44% of range
Low
$1.56
Current
$3.30
High
$5.48
Company Overviewwww.cellectis.com
About the company
Cellectis S. A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies.
- CEO
- Andre Choulika
- IPO
- 2015
- Employees
- 216
- HQ
- Paris, FR
Price Chart
+100.00% · this period
Valuation
- Market Cap
- $331.38M
- P/E
- -4.84
- P/S
- 3.47
- P/B
- 5.48
- EV/EBITDA
- -6.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.86%
- Op Margin
- -69.23%
- Net Margin
- -98.69%
- ROE
- -80.61%
- ROIC
- -27.24%
Growth & Income
- Revenue
- $72.95M · 75.76%
- Net Income
- $-67,593,000 · -83.87%
- EPS
- $-0.68 · -65.85%
- Op Income
- $-33,076,000
- FCF YoY
- -317.70%
Performance & Tape
- 52W High
- $5.48
- 52W Low
- $1.56
- 50D MA
- $3.46
- 200D MA
- $3.82
- Beta
- 2.75
- Avg Volume
- 38.61K
Get TickerSpark's AI analysis on CLLS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · CLLS
Our CLLS coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on CLLS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLLS report →Internal Compare
Similar companies
Peers in the same neighborhood.